Ricovr Healthcare is developing XALIVA®, an automated point-of-care platform designed to provide accurate THC quantification in saliva. The company positions XALIVA® as a solution to improve on-site drug screening and public safety. Ricovr’s technology leverages advanced optical detection and aims to deliver precise, immediate results. The NIH SBIR grant will support development toward an effective, scalable, and accurate device. Ricovr’s product pipeline also includes rapid point-of-care tests for drug screening, reproductive health, and infectious diseases. The company highlights a management team of scientists and engineers, a distinguished advisory board, and academic and industry partners supporting its efforts. RICOVR Healthcare builds the XALIVA rapid diagnostics platform, a saliva-based biosensor that uses a small amount of saliva to deliver lab-quality, quantified, low-cost diagnostics in about five minutes. Its product pipeline includes rapid point-of-care tests for COVID-19, THC and other drugs-of-abuse, and infectious diseases. Pre-validation testing results have shown the platform can successfully identify various biomarkers, and the company has received multiple awards for XALIVA. Management includes CEO and Founder Dr. Himanshu Bhatia and COO and Co-Founder Piyush Sadana, and the company reports partnerships with research institutions and medical device manufacturers globally. RICOVR plans to use new funding to complete platform development, scale up production capabilities, and drive commercialization and go-to-market efforts. Target customers cited include large employers in construction, transportation, retail and manufacturing, as well as law enforcement for roadside pre-screening. The company has raised capital to support commercialization and execution.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2021